Hanmi Science Co.,Ltd
Financials
Valuation Metrics
Hanmi Science Co.,Ltd's Market Cap is ₩3.0T. At end of 2025 it was ₩2.5T. Ranked #138 of 2,405 in KR market (top 6%), #122 of 778 on KOSPI (top 16%), #2 of 94 in Health Care Equipment & Services (top 2%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.98T KRW | KR#138/2,405 Sec#2/94 |
| Revenue | 1.41T KRW | KR#330/2,405 Sec#1/94 |
| Net Income | 150.89B KRW | KR#186/2,405 Sec#1/94 |
| Total Assets | 1.53T KRW | KR#369/2,405 Sec#3/94 |
| Net Assets | 1.06T KRW | KR#282/2,405 Sec#2/94 |
| Employees | 453 | KR#541/2,405 Sec#12/94 |
| Value | ||
| P/E | 19.74x | KR#1,199/2,405 Sec#37/94 |
| P/B | 2.81x | KR#2,117/2,405 Sec#75/94 |
| PEG | 0.12x | KR#468/2,405 Sec#22/94 |
| P/S | 2.12x | KR#1,878/2,405 Sec#57/94 |
| EV/EBITDA | 18.04x | KR#1,000/2,405 Sec#33/94 |
| Profitability | ||
| ROE | 14.22% | KR#358/2,405 Sec#11/94 |
| ROA | 9.85% | KR#282/2,405 Sec#14/94 |
| Op. Margin | 12.06% | KR#419/2,405 Sec#25/94 |
| Revenue Growth | 6.30% | KR#1,111/2,405 Sec#62/94 |
| Earnings Growth | 165.36% | KR#280/2,405 Sec#16/94 |
| Financial Health | ||
| Debt Ratio | 44.44% | KR#868/2,405 Sec#48/94 |
| Total Debt | 182.72B KRW | KR#538/2,405 Sec#6/94 |
| Cash | 98.28B KRW | KR#477/2,405 Sec#5/94 |
| Current Ratio | 0.90x | KR#1,824/2,405 Sec#82/94 |
| Net Debt/EBITDA | 0.50x | KR#669/2,405 Sec#27/94 |
| Dividend | ||
| Div. Yield | 0.69% | KR#1,222/2,405 Sec#37/94 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/94 |
| Performance | ||
| 1Y Return | 10.53% | KR#437/2,405 Sec#9/94 |
| 1M Return | -21.25% | KR#1,938/2,405 Sec#82/94 |
| From 52W High | -36.42% | KR#635/2,405 Sec#20/94 |
| 1Y MDD | -48.52% | KR#893/2,405 Sec#33/94 |
| Trading | ||
| Volume | 151,817 shares | KR#475/2,405 Sec#18/94 |
| Trading Value | 6.63B KRW | KR#260/2,405 Sec#7/94 |
| Foreign Own. | 1.19% | KR#1,942/2,405 Sec#69/94 |
| Per Share | ||
| EPS | 2,206 KRW | KR#422/2,405 Sec#9/94 |
| BPS | 15,514 KRW | KR#680/2,405 Sec#9/94 |
Company Info
Hanmi Science, established in 1973, received approval for conversion to a holding company in 2011. In 2022, it merged with Hanmi Healthcare, adding a healthcare business division and transforming into an operating holding company. It generates profit through equity gains from subsidiaries, patent and trademark royalty income, healthcare business, and affiliate management, holding 8 subsidiaries including Hanmi Pharmaceutical. As an operating holding company, it is dedicated to discovering new growth engines, sharing new drug development risks, and establishing mid-to-long-term visions to lead the rapidly changing global healthcare market. Hanmi Science is headquartered in Hwaseong-si, Gyeonggi-do.